financetom
Business
financetom
/
Business
/
India's Hindalco beats Q2 profit view on higher aluminium prices
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
India's Hindalco beats Q2 profit view on higher aluminium prices
Nov 11, 2024 6:18 AM

Nov 11 (Reuters) - India's Hindalco Industries

, one of the country's largest aluminium and copper

producers, posted a higher-than-expected second-quarter profit

on Monday, helped by higher aluminium prices.

The company, owned by the Aditya Birla Group, said its

consolidated net profit jumped 78% to 39.09 billion rupees

($463.3 million) for the three months ended Sept. 30, beating

estimates.

Analysts, on average, had expected a profit of 34.46 billion

rupees, according to data compiled by LSEG.

($1 = 84.3700 Indian rupees)

(Reporting by Anuran Sadhu in Bengaluru; Editing by Sumana

Nandy and Abinaya Vijayaraghavan)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Form 8.3
Form 8.3
Mar 16, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Form 8.3
Form 8.3
Mar 16, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
CytomX Therapeutics Details Phase 1 Trial Results For Colorectal Cancer Treatment
CytomX Therapeutics Details Phase 1 Trial Results For Colorectal Cancer Treatment
Mar 16, 2026
08:12 AM EDT, 03/16/2026 (MT Newswires) -- CytomX Therapeutics ( CTMX ) said Monday a Phase 1 clinical trial evaluating varsetatug masetecan in patients with advanced colorectal cancer yielded confirmed response rates of up to 32%. Patients receiving the 10-milligram per kilogram dose demonstrated an estimated median progression-free survival of 7.1 months, the company said. The 8.6-milligram per kilogram cohort...
Monte Rosa Therapeutics Signs Supply Deal With Johnson & Johnson for Phase 2 Prostate Cancer Study
Monte Rosa Therapeutics Signs Supply Deal With Johnson & Johnson for Phase 2 Prostate Cancer Study
Mar 16, 2026
08:13 AM EDT, 03/16/2026 (MT Newswires) -- Monte Rosa Therapeutics ( GLUE ) said Monday it has entered a clinical supply agreement with Johnson & Johnson ( JNJ ) to evaluate investigational drug MRT-2359 in combination with Erleada in patients with metastatic castration-resistant prostate cancer with androgen receptor mutations. Under the agreement, Monte Rosa Therapeutics ( GLUE ) will sponsor...
Copyright 2023-2026 - www.financetom.com All Rights Reserved